Drug Trial Radar · NCT07489066
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jun 30, 2026
Primary completion
Jul 29, 2028
Study completion Jul 30, 2031
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Mar 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well it works when given alone or with chemotherapy. The study is for adults with early stage or locally advanced non-small cell lung cancer (NSCLC) that may or may not be removable with surgery. The study is seeking participants who: * Are aged 18 years or older * Have either: * Early-stage or locally advanced (Stage II or IIIA/B) NSCLC and are a candidate for neoadjuvant therapy, followed by surgical removal of the tumor. Neoadjuvant therapy is a treatment given as a first step to shrink the tumor before surgery. * Early-stage or locally advanced (Stage II or IIIA/B) NSCLC and are a candidate for adjuvant therapy and did not achieve a pathological complete response (pCR) from approved treatment that was administered before surgery. Adjuvant therapy is an additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back. pCR is defined as absence of viable tumor in all surgically removed samples. * Locally advanced (Stage III) NSCLC that may not be removable with surgery, was treated with concurrent chemoradiotherapy (cCRT), and is a candidate for additional treatment, otherwise known as consolidation therapy. cCRT is chemotherapy and radiation given simultaneously. * Be in good physical condition and have healthy organs based on medical tests. * Do not have known actionable changes in DNA The study has 3 parts and each participant will be assigned to one part by their doctor based on their disease diagnosis: * Part A will test PF-08634404 given with chemotherapy in the neoadjuvant setting, followed by surgery. * Part B will test PF-08634404 alone in adults who already were treated with neoadjuvant chemo-immunotherapy, underwent surgery, and did not achieve pCR per tumor tissue pathology analysis. Neoadjuvant chemo-immunotherapy refers to the combination of chemotherapy with immunotherapy per local standard-of-care, given before surgical removal of the tumor. * Part C will test PF-08634404 alone in adults with unresectable disease who received cCRT and did not have progressive disease. Progressive disease refers to a condition that grows, spreads, or worsens. All treatments will be done at clinical study sites, where a trained medical team will monitor adults during and after each visit.
Conditions
- Carcinoma
- Non-Small-Cell Lung
- Lung Cancer (NSCLC)
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung (NSCLC)
- Lung Disease
- Non-Small Cell Lung Cancer
- Non-small Cell Lung Cancer, Non-squamous
- Non-small Cell Lung Cancer, Squamous
Interventions
PF-08634404Biological
Concentrate for solution for infusion
Chemotherapy Regimen 1Drug
Injection for intravenous use
Chemotherapy Regimen 2Drug
Injection for intravenous use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs)Time frame: Through 90 days after the last dose of study intervention (Part A only: or 90 days after surgery, whichever is later)
- Part A: Surgical Feasibility RateTime frame: Up to approximately 6 months after first dose
- Part A: Pathological Complete Response (pCR) rate per International Association for the Study of Lung Cancer (IASLC) guidelines as assessed by central pathology reviewTime frame: Up to approximately 6 months after first dose
Locations
37 sites in 11 countries. Site status is shown where the registry gives one.
Clearview Cancer Institute (Crestwood)
Huntsville, Alabama · Recruiting
Clearview Cancer Institute
Huntsville, Alabama · Recruiting
Stanford Cancer Institute
Stanford, California · Recruiting
Stanford Hospital and Clinics
Stanford, California · Recruiting
Stanford Hospital Investigational Drug Services
Stanford, California · Recruiting
University Cancer & Blood Center, LLC
Athens, Georgia · Recruiting
Hope and Healing Clinical Research
Hinsdale, Illinois · Recruiting
Hope and Healing Clinical Research
New Lenox, Illinois · Recruiting
Nebraska Medicine- Bellevue Medical Center
Bellevue, Nebraska · Not yet recruiting
Cancer Partners of Nebraska
Lincoln, Nebraska · Recruiting
Nebraska Medicine
Omaha, Nebraska · Not yet recruiting
Nebraska Medicine - Village Pointe
Omaha, Nebraska · Not yet recruiting
University of Nebraska Medical Center
Omaha, Nebraska · Not yet recruiting
New Mexico Oncology Hematology Consultants, Ltd
Albuquerque, New Mexico · Recruiting
University of Tennessee Medical Center
Knoxville, Tennessee · Recruiting
Western Health-Sunshine & Footscray Hospitals
St Albans, Victoria, Australia · Recruiting
Beijing Cancer hospital
Beijing, Beijing Municipality, China · Recruiting
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Recruiting
The Affiliated Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
LungenClinic Grosshansdorf
Großhansdorf, Germany · Not yet recruiting
Marien Hospital Düsseldorf
Düsseldorf, North Rhine-Westphalia, Germany · Not yet recruiting
Prince of Wales Hospital
Hong Kong, Hong Kong · Not yet recruiting
Sourasky Medical Center
Tel Aviv, TELL ABĪB, Israel · Recruiting
Casa di Cura Dott. Pederzoli
Peschiera del Garda, Verona, Italy · Not yet recruiting
Dolnośląskie Centrum Onkologii, Pulmonologii i Hematologii
Wroclaw, Poland · Recruiting
Pan American Center for Oncology Trials, LLC - Bayamón Office
Bayamón, Puerto Rico · Recruiting
Pan American Center for Oncology Trials, LLC - Manati Office
Manati, Puerto Rico · Recruiting
Pan American Center for Oncology Trials, LLC - Ponce Office
Ponce, Puerto Rico · Recruiting
Hospital Oncologico Dr. Isaac Gonzalez Martinez
Rio Piedras, Puerto Rico · Recruiting
Pan American Center for Oncology Trials, LLC - Ciudadela Office
San Juan, Puerto Rico · Recruiting
Hospital Universitario Puerta de Hierro de Majadahonda
Majadahonda, Spain · Recruiting
Chung Shan Medical University Hospital
Taichung, Taiwan · Recruiting
National Cheng Kung University Hospital
Tainan, Taiwan · Recruiting
National Taiwan University Hospital
Taipei, Taiwan · Not yet recruiting
Taipei Medical University Hospital
Taipei, Taiwan · Recruiting
Taipei Veterans General Hospital
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.